Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT07157033

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Led by Xerient Pharma · Updated on 2026-05-01

36

Participants Needed

4

Research Sites

447 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.

CONDITIONS

Official Title

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Cytologic or biopsy confirmed adenocarcinoma of the pancreas
  • Disease suitable for SBRT, including locally advanced, unresectable, or anatomically resectable but not surgical candidate
  • No distant metastatic disease before or after first-line systemic therapy
  • Completion of medically indicated first-line systemic therapy (e.g., FOLFIRINOX, gemcitabine/abraxane)
  • Age 18 years or older
  • ECOG performance status 0, 1, or 2
  • Adequate blood counts: neutrophils ≥1500/mm3, hemoglobin ≥8.0 g/dL, platelets ≥75,000/mm3
  • Adequate liver function: bilirubin ≤1.5x upper limit normal, AST and ALT ≤2.5x upper limit normal
  • Baseline serum calcium ≥8.4 mg/dL
  • No significant abnormal ECG findings (normal sinus rhythm, QTcF ≤470 msec, QRS ≤110 msec, PRS ≤220 msec)
  • Ability and willingness to comply with study procedures
  • Written informed consent
  • Women of childbearing potential must use effective contraception before and for 6 months after radiotherapy; men with partners of childbearing potential must use contraception during and for 3 months after radiotherapy
Not Eligible

You will not qualify if you...

  • Prior radiotherapy to upper abdomen overlapping planned SBRT field
  • Prior radiopharmaceutical therapy
  • Prior surgical removal of pancreatic tumor
  • Active or uncontrolled gastric or duodenal ulcers within 30 days
  • Visible tumor invasion into bowel or stomach lumen on endoscopy
  • Ongoing grade 3 or higher non-hematological toxicity from chemotherapy
  • Participation in another interventional trial or investigational agent use within 30 days
  • Uncontrolled illnesses including active infection, heart failure, unstable angina, renal failure, or arrhythmias
  • History of heart attack or unstable angina within 6 months
  • History of severe hypocalcemia or hypoparathyroidism
  • Unsafe hypertension management or low blood pressure at screening
  • Liver or kidney disease affecting drug metabolism or assessments
  • History of serious cardiac arrhythmias or electrical instability
  • Medical conditions requiring treatment during study or likely to prevent study completion
  • Inability to fast 3 hours before study drug administration
  • Active hepatitis B/C or HIV without stable anti-retroviral therapy
  • Blood donation or loss over 500 ml within 30 days
  • Difficulty with venous access or unwillingness for catheter insertion
  • Pregnant or breastfeeding women
  • Study staff or immediate family members involved in study
  • Investigator judgment of unsuitability or non-compliance risk

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

City of Hope

Duarte, California, United States, 91010

Actively Recruiting

2

CIty of Hope

Irvine, California, United States, 92618

Actively Recruiting

3

Christus St. Vincent Regional Cancer Center

Santa Fe, New Mexico, United States, 87505

Actively Recruiting

4

Oncology Consultants, P.A.

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

R

Robbin Frnka

CONTACT

J

Jeanne Jones

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here